Related by context. All words. (Click for frequent words.) 70 HAART 69 antiretroviral therapy 67 HAART regimens 67 antifungal therapy 66 antiviral therapies 66 virological response 66 NNRTI 66 antiretroviral regimens 66 NNRTIs 65 treatment regimens 65 antibiotic therapy 65 protease inhibitor PI 65 antiretroviral therapy ART 64 virologic failure 64 HCV 64 therapeutic regimens 64 immunosuppressive regimens 64 ribavirin therapy 64 peginterferon 64 adjuvant therapy 64 imatinib therapy 63 postexposure prophylaxis 63 cART 63 APTIVUS r 63 TroVax ® 63 virological failure 63 ribavirin RBV 63 HCV infected 63 EGFR TKI 63 HAART regimen 63 dasatinib 63 antimicrobial prophylaxis 63 antidepressant therapy 63 genotypic resistance 63 mRCC 63 nitazoxanide 63 PegIFN RBV 62 hepatitis C genotype 62 suppressive therapy 62 potent antiretroviral therapy 62 CMV infection 62 antibiotic prophylaxis 62 trimethoprim sulfamethoxazole 62 HBV infection 62 NRTIs 62 immunomodulatory therapy 62 CMV disease 62 interferon therapy 62 disease progression 62 empiric therapy 62 cotrimoxazole prophylaxis 62 isoniazid 62 imatinib 62 CCR5 antagonist 62 interferon 62 CCR5 tropic 62 NRTI 62 Liver transplantation 62 corticosteroid therapy 62 metastatic RCC 61 lamivudine 61 Cethromycin 61 combination antiretroviral therapy 61 warfarin therapy 61 HCV infection 61 forodesine 61 reperfusion therapy 61 KRAS mutation 61 peg interferon 61 immunosuppression 61 candidemia 61 antiretroviral therapies 61 EGFR inhibitors 61 virologic 61 NAbs 61 tamoxifen therapy 61 PrEP 61 HBV vaccine 61 trastuzumab Herceptin ® 61 pharmacologic intervention 61 immunosuppressive therapies 61 entecavir 61 INTELENCE 61 Hydroxyurea 61 prophylactic treatment 61 MyVax R 60 herpes zoster vaccine 60 LTBI 60 antiretroviral regimen 60 viral suppression 60 nucleoside analogues 60 superinfection 60 polysaccharide vaccines 60 immunosuppressant therapy 60 stavudine d4T 60 protease inhibitors 60 seroconversion 60 curative therapy 60 APTIVUS 60 recurrent genital herpes 60 recurrent glioblastoma multiforme 60 ARV therapy 60 therapeutic interventions 60 Telbivudine 60 APTIVUS ritonavir 60 chemotherapy regimens 60 NRTI backbone 60 NNRTI resistance 60 latent tuberculosis infection 60 ganciclovir 60 antithrombotic therapy 60 enfuvirtide 60 chlamydial infection 60 PREZISTA r 60 colorectal liver metastases 60 raltegravir 60 sustained virologic response 60 gemifloxacin 60 lymph node dissection 60 nelfinavir 60 sustained virological response 60 mycophenolate mofetil 60 talabostat 59 pneumococcal vaccination 59 antiplatelet therapy 59 virologic suppression 59 immunological responses 59 tipranavir 59 posaconazole 59 adalimumab Humira 59 immunosuppressive agents 59 integrase inhibitor 59 HBeAg negative 59 imatinib Gleevec 59 chemoprophylaxis 59 active antiretroviral therapy 59 nonvaccine 59 cytotoxic chemotherapy 59 BYSTOLIC 59 cytoreduction 59 TNF inhibitor 59 virologic responses 59 postexposure 59 iclaprim 59 rifamycins 59 interferon ribavirin 59 antibody titer 59 aromatase inhibitor therapy 59 viral kinetics 59 antiviral 59 docetaxel chemotherapy 59 TDF FTC 59 OMAPRO 59 abatacept 59 chemoradiotherapy 59 metastatic malignant melanoma 59 antiretroviral medications 59 pyridostigmine 59 Torisel 59 cidofovir 59 revaccination 59 hepatitis C virus 59 neoadjuvant chemotherapy 59 cervical lesions 59 EBV infection 59 latent TB infection 59 infliximab 59 gastrointestinal stromal tumors GIST 59 CD8 responses 59 prophylaxis 59 adefovir 59 disease modifying antirheumatic 59 invasive candidiasis 59 Telintra 59 VFEND 59 tuberculin skin test 59 nucleoside analogs 59 KETEK 59 HIV coinfected 59 Ribavirin 59 amphotericin B 59 Trastuzumab 59 prophylactic antibiotics 59 dasatinib Sprycel 59 CCR5 antagonists 58 tuberculin skin testing 58 ganetespib 58 antiviral prophylaxis 58 antituberculosis 58 Imatinib 58 protease inhibitors PIs 58 Altastaph 58 pegylated alpha interferon 58 receptor tyrosine kinase inhibitor 58 renal transplantation 58 serologic testing 58 maraviroc 58 anticancer therapies 58 vaginal microbicides 58 Therapy HAART 58 Gleevec imatinib 58 nephrotoxicity 58 intravenous bisphosphonates 58 achieve sustained virologic 58 nucleotide analog 58 alteplase 58 zidovudine AZT 58 NRTI resistance 58 meningococcal vaccines 58 sorafenib Nexavar 58 antithrombotic 58 N. gonorrhoeae 58 IGRAs 58 pharmacologic treatments 58 glucocorticoid therapy 58 Interferon alpha 58 virologic response 58 antiretroviral treatment 58 neoadjuvant therapy 58 fulvestrant 58 Vacc 4x 58 metastatic kidney 58 pegylated interferon 58 MYCAMINE 58 invasive aspergillosis 58 Gleevec resistant 58 recurrent glioma 58 viral load 58 biologic therapy 58 Combination therapy 58 HBV 58 antihypertensive therapy 58 alfa 2a 58 nucleotide analogs 58 HSCT 58 pyrazinamide 58 WNV infection 58 HBsAg 58 ritonavir boosted 58 neutropenic patients 58 antibiotic regimens 58 Doxil ® 58 anti leukemic 58 cytotoxic therapy 58 co trimoxazole 58 rituximab 58 daptomycin 58 lupus nephritis 58 nanoviricide 58 empiric treatment 58 chemotherapeutic 58 Adjuvant chemotherapy 58 dosing regimens 58 Velcade bortezomib 58 tipranavir ritonavir 58 sunitinib 58 pimozide 58 nucleoside reverse transcriptase inhibitor 58 ISENTRESS 58 refractory chronic myeloid 58 chemotherapeutic regimens 58 Virologic 58 HBeAg 58 canakinumab 58 Gag polymorphisms 58 abiraterone 58 predictive biomarkers 58 tyrosine kinase inhibitors 58 antiplatelet therapies 58 radioiodine therapy 58 coinfected patients 58 trastuzumab Herceptin 58 adalimumab 58 ceftriaxone 58 AZT zidovudine Retrovir 58 LMWH 58 poliovirus vaccine 58 BRAF mutation 58 rhGH 58 hormonal therapies 58 chronic HCV 58 lenalidomide dexamethasone 58 Darunavir 58 TMP SMX 58 oral anticoagulation 58 virologically 58 therapies 58 SCIg 58 statin medications 58 nucleoside analogue 58 MMP inhibitors 58 T#I mutation 58 Antiviral drugs 58 MyVax 58 androgen deprivation 58 BRAF V# mutation 58 neoadjuvant treatment 58 neutralizing antibody 58 aldosterone antagonists 58 HCV genotype 1 58 cisplatin chemotherapy 58 GnRH agonists 58 rBChE 58 colorectal cancer liver metastases 58 antiviral efficacy 58 quinolone 57 Cytolin R 57 d4T stavudine Zerit 57 virological 57 K ras mutations 57 ChronVac C ® 57 TNFa 57 CCR5 inhibitor 57 relapsed SCLC 57 cranial irradiation 57 KRAS mutant tumors 57 peginterferon alfa 2a 57 heavily pretreated 57 erlotinib Tarceva 57 adjuvant therapies 57 Bcr Abl mutations 57 Candida species 57 DMARD 57 antitumor effect 57 AZOR 57 amoxicillin clavulanate 57 HCV SPRINT 57 sulfadoxine pyrimethamine 57 chronic HCV infection 57 AGILECT R 57 artemisinins 57 VIRAMUNE 57 HCV replicon 57 LHRH antagonists 57 Influenza vaccination 57 lapatinib Tykerb 57 leflunomide 57 tocilizumab 57 rhTSH 57 DermaVir Patch 57 COPD exacerbations 57 virus HBV 57 micafungin 57 PROCHYMAL 57 Tolamba 57 P. vivax malaria 57 Rifampin 57 gonococcal infections 57 Dasatinib 57 serologic 57 boosted protease inhibitor 57 ribavirin 57 H#Y 57 mupirocin 57 prophylactically 57 nucleoside analog 57 alkylating agent 57 dasatinib Sprycel ® 57 apricitabine 57 ritonavir boosted protease inhibitor 57 TNF therapy 57 myeloablative 57 VZV 57 multidrug resistance 57 curative resection 57 VICTRELIS 57 vandetanib 57 nevirapine Viramune 57 inhibitor RG# 57 protease inhibitor 57 FluCide 57 BCG vaccine 57 TKI therapy 57 INCB# [001] 57 Infected Patients 57 trivalent vaccine 57 adjuvant tamoxifen 57 griseofulvin 57 temsirolimus 57 Twinrix 57 Hiberix 57 TYGACIL 57 concomitant antibiotics 57 NSAID therapy 57 Phase IIb trials 57 riociguat 57 Pegylated Interferon 57 leukotriene receptor antagonist 57 nucleotide analogue 57 rhinovirus infection 57 CCR5 inhibitors 57 pertussis vaccination 57 chronic GVHD 57 pyrimethamine 57 gefitinib 57 Talabostat 57 VAX# 57 Cytolin 57 imatinib resistance 57 thromboprophylaxis 57 SUTENT 57 VTE prophylaxis 57 antioxidant supplementation 57 GIST tumors 57 response CCyR 57 leukemia ALL 57 Aspergillus infections 57 biologic DMARD 57 HCV genotypes 57 chlamydial 57 ofpatients 57 velafermin 57 CCR5 tropic HIV 57 pertuzumab 57 pathogenic viruses 57 refractory CLL 57 relapsed AML 57 standard chemotherapy regimens 57 lamivudine refractory patients 57 relapsed ovarian cancer 57 dopaminergic therapy 57 live attenuated vaccines 57 adjuvant radiotherapy 57 anagrelide 57 relapsing MS 57 peg IFN 57 NS4A 57 Bortezomib 57 alefacept 57 bortezomib 57 TORISEL 57 ISTODAX 57 ART regimens 57 peginterferon alfa 57 anti TNF 57 PEG interferon 57 pertussis Tdap vaccine 57 tigecycline 57 immunopathology 57 glatiramer acetate 57 antiretroviral naive 57 pDCs 57 sipuleucel T 56 VP# [004] 56 CYP#A# inhibitors 56 anticoagulation therapy 56 hypersensitivity reaction 56 tyrosine kinase inhibitor 56 immunosuppressive drugs 56 paclitaxel Taxol 56 Cytolin ® 56 systemic corticosteroids 56 tetravalent vaccine 56 siRNA therapeutics 56 lipid lowering therapy 56 indinavir 56 vidofludimus 56 HCV infections 56 bisphosphonate therapy 56 type 1diabetes 56 Amigal 56 voriconazole 56 Reverset 56 severe oral mucositis 56 complete cytogenetic response 56 serum HBV DNA 56 chronic HBV 56 post exposure prophylaxis 56 chemotherapeutic regimen 56 APTIVUS R 56 Rimantadine 56 metastatic renal cell carcinoma 56 neuraminidase inhibitor 56 Pafuramidine 56 MULTAQ 56 GnRH antagonist 56 bevirimat 56 K#N 56 mcg dose 56 bendamustine 56 MAGE A3 ASCI 56 immunotherapy 56 Kinoid 56 mg kg dose 56 EGFR mutation 56 lenalidomide Revlimid R 56 hour bronchodilation 56 signal transduction inhibitors 56 chickenpox vaccinations 56 HIV HCV coinfected 56 etravirine 56 therapies ACTs 56 androgen ablation 56 BARACLUDE 56 rifabutin 56 Noxafil 56 XmAb# 56 Thiovir 56 immunomodulators 56 pegylated interferon alfa 56 posttransplant 56 cytomegalovirus infection 56 low dose ritonavir 56 ESBLs 56 dosage regimens 56 uric acid lowering 56 viral replication 56 viremia 56 FLT3 56 anti retroviral therapy 56 mitochondrial toxicity 56 trastuzumab 56 immunosuppressed patients 56 intradermal injection 56 DMARDs 56 hepatitis C HCV 56 pharmacokinetic interactions 56 HBeAg positive patients 56 inactivated influenza vaccines 56 log# reduction 56 EPZICOM 56 invasive fungal infections 56 thalidomide Thalomid 56 liver transplantation 56 humoral responses 56 anti tubercular 56 HCV genotype 56 Valcyte 56 ICD implantation 56 idarubicin 56 antibody mediated 56 neurotrophic 56 darunavir 56 DAPT 56 MDS AML 56 hydroxychloroquine 56 pelvic lymphadenectomy 56 Bezielle 56 Decitabine 56 chemotherapies 56 varicella vaccine 56 efavirenz Sustiva 56 intensive statin therapy 56 nephrotoxic drugs 56 superficial bladder cancer 56 antiviral drugs 56 vicriviroc 56 DermaVir 56 peptide antigens 56 pimecrolimus 56 monovalent vaccine 56 liver transplant recipients 56 T#I [002] 56 bevacizumab Avastin ® 56 visilizumab 56 coinfection 56 surrogate endpoint 56 R0 resection 56 resminostat 56 single dose nevirapine 56 hormonal therapy 56 somatostatin analogs 56 Neisseria gonorrhoeae 56 adefovir dipivoxil 56 e antigen HBeAg 56 Hedgehog inhibitor 56 VIR# 56 Immunosuppressive drugs 56 hepatic fibrosis 56 Q#IR 56 anti TNFs 56 immunosuppressive medication 56 pertussis toxin 56 cytotoxic effects 56 herpes infections 56 Antiretroviral therapy 56 omega interferon 56 antibody MAb 56 Dr. McHutchison 56 ponatinib 56 OHR/AVR# 56 anakinra 56 heavily pretreated patients 56 neutralizing antibodies 56 imipenem 56 Intravenous CP 56 β blockers 56 Bcl xL 56 caspofungin 56 atazanavir 56 LAIV 56 Peg IFN 56 palliative radiotherapy 56 vaccine LAIV 56 HspE7 56 PRT# 56 KRAS status 56 FROVA 56 adjuvant chemotherapy 56 severe neutropenia 56 oral methylnaltrexone 56 penicillin allergy 56 chlorambucil 56 antidiabetic therapy 56 taxane chemotherapy 56 Cyclosporine 56 BCG vaccination 56 Candida infection 56 nanoviricides 56 Prophylaxis 56 antiplatelet agents 56 Pseudomonas aeruginosa infections 56 Valortim R 56 BCR ABL mutations 56 HGS# 56 octreotide 56 antiplatelet drugs 56 antiretroviral drugs 56 Immunotherapy 56 ritonavir boosted lopinavir 56 IFN beta 56 antibody responses 56 trastuzumab DM1 T DM1 56 doxorubicin docetaxel 56 otelixizumab 56 lamivudine resistant 56 taxane therapy 56 stavudine 56 valganciclovir 56 TKIs 56 virus HCV infection 56 infliximab Remicade 56 antiretroviral ARV therapy 56 allogeneic SCT 56 gefitinib Iressa 56 Epstein Barr virus EBV 56 antiretroviral naïve 55 pentoxifylline 55 Copegus ribavirin 55 decitabine 55 EGFR tyrosine kinase inhibitors 55 antiviral compounds 55 radezolid 55 abacavir lamivudine 55 HCV antibody 55 Mitoxantrone 55 renal flares 55 valproic acid 55 SPRYCEL ® 55 natalizumab 55 rifampicin 55 CTAP# Capsules 55 HGS ETR1 55 HBeAg seroconversion 55 bevacizumab Avastin 55 trabectedin 55 eosinophilic asthma 55 adeno associated viruses 55 enterococcal 55 prostate cancer CaP 55 anticoagulation 55 fluoroquinolone resistance 55 antibiotic 55 itraconazole 55 overlapping toxicities 55 ISF# 55 HIV infected 55 piperacillin tazobactam 55 Natalizumab 55 EXJADE 55 anti VEGF 55 liver metastases 55 Pharmacokinetics PK 55 rilonacept 55 nilotinib 55 Saquinavir 55 DACH platinum 55 Artesunate 55 Delcath System 55 cabazitaxel 55 NS5b 55 ALI ARDS 55 lipid lowering therapies 55 Blinatumomab 55 AMEVIVE 55 oral prodrug 55 verteporfin 55 Amantadine 55 Traficet EN 55 MYLOTARG 55 cilengitide 55 EGFR pathway 55 chronic eosinophilic leukemia 55 docetaxel 55 solid organ transplantation 55 antihypertensive drugs 55 LCMV infection 55 IRX 2 55 HCV polymerase inhibitor 55 immunosuppressive medications 55 palivizumab 55 PTLD 55 GeoVax vaccine 55 anti retroviral therapies 55 Panzem R NCD 55 antiandrogens 55 methotrexate therapy 55 relapsed ALL 55 cystectomy 55 antiretrovirals 55 suppress viral replication 55 topotecan 55 CYT# potent vascular disrupting 55 surface antigen HBsAg 55 intramuscular injections 55 pomalidomide 55 efalizumab 55 beta blocker therapy 55 pegfilgrastim 55 EGFRIs 55 SELZENTRY 55 invasive fungal infection 55 alpha blocker 55 mAbs 55 Pegasys peginterferon alfa 2a 55 interferon alfa 55 Lung transplantation 55 complete cytogenetic 55 Gefitinib 55 Pneumocystis carinii pneumonia 55 ACZ# 55 Fingolimod 55 achieved sustained virological 55 Di Bisceglie 55 Phase Ib study 55 Edurant 55 Merck Isentress 55 HBV DNA 55 adjuvanted vaccines 55 IRESSA 55 DOXIL 55 CCyR 55 platelet transfusions 55 pneumococcal infection 55 SCCHN 55 FASLODEX 55 SIV infected 55 celgosivir 55 preoperative chemotherapy 55 immune suppression 55 chemoradiation 55 receiving immunosuppressive therapy 55 PPSV# 55 anticancer therapy 55 rifapentine 55 ertapenem 55 resectable 55 CsA 55 Glivec imatinib 55 adjuvant radiation 55 DMARD therapy 55 S. aureus colonization 55 bevacizumab Avastin Genentech 55 oral JAK1 55 prognostic markers 55 BEXXAR Therapeutic Regimen 55 alpha 2a 55 undetectable HCV RNA 55 saquinavir 55 refractory gout 55 tenofovir Viread 55 CD4 counts 55 tumor necrosis 55 intravesical 55 Chlamydia trachomatis 55 BARACLUDE ® 55 retroviral 55 Allovectin 7 ® 55 direct thrombin inhibitors 55 grade cervical intraepithelial 55 herceptin 55 FLUARIX 55 MAXY alpha 55 C. difficile toxins 55 mapatumumab 55 adjuvanted H#N# 55 H. influenzae 55 Anti virals 55 antiangiogenic therapy 55 NEUGENE 55 neurologic progression 55 ß blockers 55 REYATAZ 55 M#V mutation 55 H pylori 55 chemotherapy docetaxel 55 CANCIDAS 55 antiandrogen 55 INVEGA ® 55 hypereosinophilic syndrome 55 NOXAFIL 55 pharmacological intervention 55 Symadex 55 PEG IFN 55 hepatitis B infection 55 ketolide antibiotic 55 Tindamax R 55 prostate cancer CRPC 55 TYZEKA 55 immunosuppressant drug 55 rtPA 55 Aptivus ® 55 Hepatocellular Carcinoma HCC 55 eculizumab therapy 55 interferon IFN 55 mTOR kinase 55 rt PA 55 MenACWY 55 MCyR 55 inhibit replication 55 SHPT 55 HBeAg positive 55 antisense oligonucleotides 55 administered subcutaneously 55 NPM1 55 vemurafenib 55 methylnaltrexone 55 metastatic renal cell 55 systemic immunosuppressive drugs 55 sodium stibogluconate 55 cinacalcet 55 TNF inhibitors 55 ddI 55 curative treatments 55 erlotinib Tarceva ® 55 docetaxel Taxotere ® 55 therapeutic armamentarium 55 inactivated vaccine 55 Interferon alfa 55 multidrug resistant 55 CBLC# 55 rFVIIa 55 cefepime 55 omalizumab 55 valacyclovir 55 nifurtimox 55 cetuximab 55 coinfected 55 P. falciparum malaria 55 HER2 overexpression 55 Retreatment 55 nucleoside 55 topical microbicides 55 hematological cancers 55 presymptomatic 55 samalizumab 55 renal toxicity 55 HCV replication 55 immunomodulator 55 ovarian stimulation 55 PREZISTA 55 trivalent influenza vaccine 55 Corticosteroids 55 lamivudine 3TC 55 systemic fungal infections 55 montelukast 55 ZYVOX 55 dexamethasone Decadron 55 thrombolytic therapy 55 EGFR mutations 55 AEG# 55 BEXXAR therapeutic regimen 55 transfusion transmitted 55 NEUPOGEN 55 prophylactic therapy 55 virological suppression 55 receiving VICTRELIS 55 DAS# [001] 55 lopinavir 55 dose intramuscular 55 Protease inhibitors 55 liver biopsy 55 noscapine 55 undetectable viral load 55 tumor recurrence 55 hormone refractory 55 PCV7 vaccine 55 postoperative radiotherapy 55 liver histology 55 Myelodysplastic Syndrome MDS 55 antisense compounds 54 anticoagulant therapy 54 Fludara ® 54 paricalcitol 54 ganaxolone 54 acute GvHD 54 autologous transplant 54 co receptor tropism 54 elvucitabine 54 antiepileptic drugs AEDs 54 aldosterone antagonist 54 recombinant interferon 54 BEXXAR 54 AZILECT 54 systemic ALCL 54 TransVax TM 54 immunomodulatory 54 immune modulating 54 prodromal symptoms 54 H. pylori eradication 54 investigational therapies 54 polymerase inhibitor 54 castration resistant prostate cancer 54 Bosentan 54 aromatase inhibitor 54 immunosuppressive regimen 54 PROSTVAC VF 54 EGFR TKIs 54 influenza antiviral medications 54 detecting colorectal cancer 54 VAPRISOL 54 pegylated interferon alfa 2a 54 pre exposure prophylaxis 54 Immunotherapeutic 54 bosutinib 54 Disease Progression 54 disease modifying 54 d4T 54 intravenous immunoglobulin 54 empiric 54 Phase 2a trial 54 epithelial tumors 54 cardiotoxic effects 54 anthracycline containing 54 screening colonoscopy 54 Aliskiren 54 Kamada AAT 54 miglustat 54 anti angiogenic drugs 54 diabetic gastroparesis 54 virotherapy 54 Zevalin consolidation 54 OncoVEX GM CSF 54 ROTARIX 54 concomitant medications 54 ixabepilone 54 superantigens 54 monotherapy 54 leukemia AML 54 genital herpes infections 54 basiliximab 54 Cytoxan 54 etiologic agent 54 virus HCV 54 cotrimoxazole 54 clozapine 54 highly immunogenic 54 RRMS patients 54 Vidofludimus 54 TTF Therapy 54 Alemtuzumab 54 stage IIIB 54 penicillin G benzathine 54 antiemetics 54 antiepileptics 54 Mantoux test 54 Degarelix 54 P. falciparum parasites 54 HIV1 54 IV bisphosphonates 54 nebulization 54 CHOP chemotherapy 54 PNH patients 54 CDAD 54 serum antibody 54 immunological 54 antituberculosis drugs 54 treatment naïve genotype 54 allogeneic HSCT 54 CEQ# 54 ORENCIA ® 54 antiarrhythmic drugs 54 STELARA ® 54 VIRAMUNE XR 54 bladder carcinoma 54 pathogenic mechanisms 54 PCV7 54 immunocompromised patients 54 attenuated strain 54 hematologic abnormalities 54 CD4 + T lymphocytes 54 IFN alpha 54 Dose escalation 54 p# activation 54 BRCA mutation 54 Pegasys ® 54 dose regimen 54 hepatic toxicity 54 relapsed MM